H.C. Wainwright Keeps Their Buy Rating on Veru Inc

By Carrie Williams

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Veru Inc (NASDAQ: VERU), with a price target of $5. The company’s shares closed yesterday at $1.32.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -9.0% and a 31.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, RegeneRx Biopharmaceuticals Inc, and Biospecifics Technologies Corp.

Veru Inc has an analyst consensus of Moderate Buy, with a price target consensus of $5.

Based on Veru Inc’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $2.59 million and GAAP net loss of $4.26 million. In comparison, last year the company earned revenue of $3.24 million and had a GAAP net loss of $1.37 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Veru, Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. The company was founded by William R. Gargiulo Jr. and O.B. Parrish on 1971 and is headquartered in Miami, FL.